Hana Pharm (293480) Fundamentals 2026 — P/E 10.1x, Revenue Analysis | SniperIQ
Hana Pharm (293480) is a KR-listed Healthcare company in Drug Manufacturers - Specialty & Generic with a market capitalization of ₩148.2B, trading at ₩8360.00 on the KSC. This SniperIQ fundamentals page covers Hana Pharm's valuation (P/E 10.1x, P/B 0.5x), profitability (net margin 6.0%), revenue (₩239.5B in FY2025), balance-sheet quality, and AI signal context — from live market data, research only.
Full research coverage
- 8-Quarter Revenue & Margin Trend
- Debt Maturity & Coverage
- Peer Valuation Comparison
- Free Cash Flow & Owner Earnings
- AI Signal + Institutional Flow
- DCF Valuation Model
Frequently Asked Questions
What is Hana Pharm's market cap?
Hana Pharm (293480) has a market capitalization of approximately ₩148.2B, trading at ₩8360.00 on the KSC. Market cap moves with the live share price.
What is Hana Pharm's P/E ratio?
Hana Pharm's trailing twelve-month P/E ratio is 10.1x, with a price-to-book (P/B) of 0.5x. Valuation multiples are best compared with Healthcare sector peers rather than read in isolation.
How profitable is Hana Pharm?
Hana Pharm runs a net profit margin of 6.0%, a gross margin of 61.6%, and an operating margin of 11.2%. Margins and ROE indicate how efficiently the business converts sales into profit and shareholder returns.
How much revenue does Hana Pharm generate?
Hana Pharm reported revenue of ₩239.5B for fiscal year 2025, with net income of ₩8.8B and earnings per share (EPS) of 507. SniperIQ tracks the full 8-quarter revenue and margin trend on the research dashboard.
Does Hana Pharm pay a dividend?
Hana Pharm offers a trailing dividend yield of about 3.1%. Dividend sustainability depends on payout ratio, free cash flow, and earnings stability — all tracked in SniperIQ's fundamentals view.
Is Hana Pharm financially healthy?
Hana Pharm carries a debt-to-equity ratio of 0.21x and a current ratio of 1.40x, with a market beta of 0.36. Lower leverage and a current ratio above 1.0 generally signal a stronger balance sheet.
Is Hana Pharm a good stock to buy in 2026?
SniperIQ provides research-only market intelligence, not personalised financial advice or a buy/sell call. For Hana Pharm (293480) the key facts are: market cap ₩148.2B, P/E 10.1x, revenue ₩239.5B, 52-week range 8170-12390. Weigh valuation, profitability, growth, and balance-sheet strength against Healthcare peers and form your own view.
Track Hana Pharm's full fundamentals live
Get Hana Pharm's 8-quarter revenue and margin trend, peer comparison, DCF model, and AI signal on the SniperIQ research dashboard.